DRUG DISCOVERY
ISSN (print) 2278–540X : ISSN (online) 2278–5396 : An official publication of Discovery Scientific Society (formerly - Discovery Publication)
Drug Discovery is an international peer reviewed publication passionate to publishing on the diverse subject categories of Pharmacology, Toxicology & Pharmaceutics. The Open access publication Drug Discovery publishes research and reviews in emerging areas of Drug Design; Drug Discovery; Pharmaceutical Science; Pharmacology, Toxicology, and Pharmaceutics (Miscellaneous) challenges to encourage scientists to publish their experimental and theoretical results in as much detail as possible.
The journal publishes reviews, research papers, analysis, survey, report, perspectives and communications in the areas of Pharma science and at the interface of related disciplines such as drug design and drug development in the Categories of Biopharmaceuticals, Biotechnology, Clinical trials, Drug delivery, Drug regulation, High-throughput screening, Industry trends, Informatics, Intellectual property, Market analysis, Medicinal chemistry, Natural products, Novel therapeutic strategies, 'Omic' technologies, Pharmacoeconomics, Pharmacogenomics, Immunology, Pharmacology, Pharmacognosy, Rational drug design, Strategic issues, Target discovery and validation, Toxicology, Vaccines.
Drug Discovery employs a double-blind external peer review process, in which the author identities are concealed from the reviewers, and vice versa, throughout the review process. The Editorial Board of the journal will immediately screen all articles submitted for publication in that journal.
Manuscripts have to be double-spaced with one-inch margins. Headings must be used to designate the major divisions of the paper. To facilitate the review process, manuscripts should contain page and line numbering. Manuscripts must be written in English. Authors whose native language is not English are strongly advised to have their manuscript checked by a language editing service, or by an English mother-tongue colleague prior to submission. As part of the submission process, authors are required to check off the Submission Preparation Checklist, and submissions may be returned to authors that do not adhere to these guidelines.
The Editor-in-Chief
Drug Discovery
E-mail: discovery@discoveryjournals.org
Discovery Scientific Society’s journals obey & follow the Committee on Publication Ethics (COPE). We plentifully adhere to COPE Core Practices and to COPE Best Practice Guidelines, except Article Withdrawal Policy. Our article withdrawal policy is explained in detail under Article Withdrawal & Substitution Policy.
Our editors & editorial members implements a hard peer-review procedure with strong ethical issues & policies towards enhancement of high-quality science & technical studies to the arena of research publication. Based on the zero-tolerance procedure, our editors of Discovery Scientific Society takes very serious implementation against falsification of data, plagiarism of scientific-content, and inappropriate author credential, with the rules & regulations of publishing ethical issues.
